Basic Information
| LncRNA/CircRNA Name | GNAS-AS1 |
| Synonyms | NA |
| Region | GRCh38_20:58818919-58850903 |
| Ensemble | ENSG00000235590 |
| Refseq | NR_002785 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | Human NSCLC cell lines (PC9, SPCA1, H358, A549, H1299) and bronchial epithelial cells (16HBE), NSCLC tissues and their adjacent normal tissues |
| Expression Pattern | up-regulated |
| Function Description | GNAS-AS1 expression was dramatically enhanced in TAM, NSCLC cell lines, and clinical tumor tissues, and negatively correlated with overall survival of NSCLC patients. GNAS-AS1 promoted macrophage M2 polarization and NSCLC cell progression via directly inhibiting miR4319, which could target N-terminal EF-hand calcium binding protein 3 (NECAB3) to inhibit its expression. GNAS-AS1/miR4319/NECAB3 axis promotes tumor progression of NSCLC by altering macrophage polarization. |
| Pubmed ID | 31267263 |
| Year | 2019 |
| Title | GNAS-AS1/miR-4319/NECAB3 axis promotes migration and invasion of non small cell lung cancer cells by altering macrophage polarization |
External Links
| Links for GNAS-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |